Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine Maintenance in TNBC
NCT00130533Phase 3Completed
- Sponsor
- GEICAM
- Start
- Jan 2006
- Primary completion
- Feb 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Capecitabine with Observation (2 arms). Primary endpoint: Disease Free Survival at 5 years. Started Jan 2006; status: completed.
02
Drugs
capecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00130533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00130533.